S&CO Inc. Invests $3.16 Million in Illumina, Inc. $ILMN

S&CO Inc. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 18,000 shares of the life sciences company’s stock, valued at approximately $3,164,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Elyxium Wealth LLC bought a new stake in Illumina during the fourth quarter valued at about $25,000. TD Waterhouse Canada Inc. bought a new position in shares of Illumina in the fourth quarter worth about $26,000. Laurel Wealth Advisors LLC bought a new position in shares of Illumina in the fourth quarter worth about $26,000. Quarry LP purchased a new position in shares of Illumina during the 3rd quarter valued at about $32,000. Finally, Activest Wealth Management lifted its position in shares of Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after buying an additional 215 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,415,351 shares of company stock worth $255,966,311 over the last ninety days. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Performance

NASDAQ:ILMN opened at $190.89 on Friday. The stock has a 50-day moving average price of $183.78 and a 200 day moving average price of $150.56. The stock has a market capitalization of $28.82 billion, a P/E ratio of 35.61, a P/E/G ratio of 2.69 and a beta of 1.45. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $207.00. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the previous year, the firm earned $1.19 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ILMN shares. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. Finally, Leerink Partners raised their price objective on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.